BTBotond Timár

Botond Timár

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Botond Timár has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • András Matolcsy

    HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    2 shared publications
  • Béla Kajtár

    Department of Pathology, Medical School, University of Pécs, 7624 Pécs, Hungary

    2 shared publications
  • Csaba Bödör

    1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

    2 shared publications
  • Csaba Bödör

    HCEMM‐SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research Semmelweis University Budapest Hungary

    2 shared publications
  • Hanna Eid

    Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary

    2 shared publications
  • Judit Demeter

    Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika

    2 shared publications

Latest Publications

  • Open Access

    Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study

    by Alex Jenei, Béla Kajtár, Tamás László, Hazem A Juratli, Livia Vida, Ágota Szepesi, Réka Mózes, Botond Timár, Jörg Halter, Stefan Dirnhofer, et al.

    Myeloid sarcoma (MS) is a tumorous extramedullary proliferation of blast or blast equivalent cells (e.g., promonocytes or promyelocytes). The most frequent cutaneous presentation is often referred to as leukemia cutis (LC). These lesions, especially without the clinical context of a known bone marrow disease, pose a differential diagnostic challenge. In this retrospective multicenter clinico‐pathological study on 154 patients with MS or LC, 169 samples were analyzed by morphology, immunohistochemistry, and fluorescent in situ hybridization, and a subset by additional sequencing [ TP53 ]. The majority of cases were lysozyme positive (diffuse in 91% and focal in 5%), 51% showed diffuse and 6% focal expression of CD56, and IRF8 was strongly positive in 31% of the lesions. Lack of myeloperoxidase (MPO), CD117, and CD34 expression was observed in 27%, 39%, and 58%, respectively. PU.1 was positive in almost all instances (95%), but BRAF V600E was consistently negative. CD123 was diffusely (13%) or focally (25%) positive, which, in addition to frequent CD4 (73%) and CD56 expression, pointed to a phenotypic overlap with blastic plasmacytoid dendritic cell neoplasms. Survival analysis revealed that MS occurring at sanctuary sites (CNS, orbit, ovary, and testis) was characterized by excellent survival. Similarly to histiocytoses, there was a prognostic difference between isolated and multisystemic involvement by MS. Patients who underwent allogeneic hematopoietic stem cell transplantation showed significantly improved survival. In conclusion, this multicenter study suggests that most MS are of myelomonocytic/monoblastic origin, a high proportion of them are NPM1 mutated, and may lack expression of MPO and CD34. NPM1 mutation‐specific antibodies should be integrated into the diagnostic panels for MS or LC, while IRF8 and PU.1 are not recommended as they cannot distinguish MS from histiocytic neoplasms.


  • Open Access

    Refrakter coeliakia

    by Krisztián Birtalan, Dóra Csikós, János Izer, Eszter Takács, Dóra Kelemen, Botond Timár, András Taller

    A 33 éves nő két olyan betegség miatt járt rendszeresen szakambulanciára, amelyek fogyáshoz is vezethetnek, de mindkét betegsége megfelelően kezeltnek látszott. A szerzők a kivizsgálás buktatóira és a tünetek újraértékelésének fontosságára hívják fel a figyelmet, de egyben bemutatják a refrakter coeliakia diagnosztikájának nehézségeit is.

  • Open Access

    A deep-learning algorithm (AIFORIA) for classification of hematopoietic cells in bone marrow aspirate smears based on nine cell classes—a feasible approach for routine screening?

    by Leonie Saft, Emma Vaara, Elin Ljung, Anna Kwiecinska, Darshan Kumar, Botond Timar

    Bone marrow cytology plays a key role for the diagnosis and classification of hematological disease and is often the first step in the acute setting of unclear cytopenia. AI applications represent a powerful tool in digital image analysis and can improve the diagnostic workflow and accuracy. The aim of this study was to develop an algorithm for the automated detection and classification of hematopoietic cells in digitized bone marrow aspirate smears for potential implementation in the clinical laboratory. The AIFORIA create platform (Aiforia Technologies, Plc, Helsinki, Finland) was used to develop a convolutional neural network algorithm based on nine cell classes. Digitized bone marrow aspirate smears from normal hospital controls were used for AI training. External validation was performed on separate data sets. Automated cell classification was assessed in whole-slide images (WSI) and regions of interest (ROI). A total of 1950 single-cell annotations were applied for AI training with a final total class error of 0.15% with 99.9% precision and sensitivity (FI-score 99.2%). External validation showed an overall precision and sensitivity of 96% and 97% and a F1-score of 96%. Automated cell classification correlated highly across ROI with variable correlation to WSI. The average execution time for classifying 500 hematopoietic cells was < 1 s and ≤ 260 s for WSI. A cloud-based, deep-learning algorithm for automated detection and classification of hematopoietic cells in bone marrow aspirate smears is a very useful, reliable, and rapid screening tool in combination with cytomorphology.


  • Open Access

    Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University

    by Kata Ferenczi, Zsófia Flóra Nagy, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter

    Introduction: Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disease. BRAF V600E mutation is detected in nearly all classical HCL cases which offers the possibility of targeted therapy.Objective: The aim of our study was to assess the efficacy of low-dose vemurafenib as well as to assess the long term outcome of HCL patients treated with this drug at the Department of Internal Medicine and Oncology at Semmelweis University.Methods: We report on 10 patients with classical HCL treated with low-dose vemurafenib at our Department between 2013 and 2022.Results: As a result of fixed time low-dose vemurafenib treatment, 5 of 10 patients (5/10) achieved partial remission, 4 (4/10) had stable disease, and 1 (1/10) had MRD positivity. No patients achieved complete remission. The median progression-free survival was 28.5 months while the overall survival was 82 months.Conclusion: We confirm that low dose of vemurafenib is effective and safe in the vast majority of patients with HCL. This small-molecule oral treatment allows to gain valuable time—months or even years—before further, usually parenteral treatment options have to be given or before previous treatment has to be repeated. There are also promising data supporting the combination of vemurafenib with other drugs for the treatment of HCL patients which could provide even further possibility to bridge treatment.


  • Open Access

    Next-Generation Sequencing–Based Genomic Profiling of Children with Acute Myeloid Leukemia

    by Szilvia Krizsán, Borbála Péterffy, Bálint Egyed, Tibor Nagy, Endre Sebestyén, Lajos László Hegyi, Zsuzsanna Jakab, Dániel J. Erdélyi, Judit Müller, György Péter, et al.


  • Open Access

    Myelofibrosis progression grading based on type I and type III collagen and fibrillin 1 expression boosted by whole slide image analysis

    by Tamas Szekely, Barna Wichmann, Mate E Maros, Annamaria Csizmadia, Csaba Bodor, Botond Timar, Tibor Krenacs

    Aims: The progression of primary myelofibrosis is characterised by ongoing extracellular matrix deposition graded based on ‘reticulin’ and ‘collagen’ fibrosis, as revealed by Gomori's silver impregnation. Here we studied the expression of the major extracellular matrix proteins of fibrosis in relation to diagnostic silver grading supported by image analysis.Methods and results: By using automated immunohistochemistry, in this study we demonstrate that the expression of both types I and III collagens and fibrillin 1 by bone marrow stromal cells can reveal the extracellular matrix scaffolding in line with myelofibrosis progression as classified by silver grading. ‘Reticulin’ fibrosis indicated by type III collagen expression and ‘collagen’ fibrosis featured by type I collagen expression were parallel, rather than sequential, events. This is line with the proposed role of type III collagen in regulating type I collagen fibrillogenesis. The uniformly strong fibrillin 1 immune signals offered the best inter‐rater agreements and the highest statistical correlations with silver grading of the three markers, which was robustly confirmed by automated whole slide digital image analysis using a machine learning‐based algorithm. The progressive up‐regulation of fibrillin 1 during myelofibrosis may result from a negative feedback loop as fibrillin microfibrils sequester TGF‐β, the major promoter of fibrosis. This can also reduce TGF‐β‐induced RANKL levels, which would stimulate osteoclastogenesis and thus can support osteosclerosis in advanced myelofibrosis.Conclusions: Through the in‐situ detection of these extracellular matrix proteins, our results verify the molecular pathobiology of fibrosis during myelofibrosis progression. In particular, fibrillin 1 immunohistochemistry, with or without image analysis, can complement diagnostic silver grading at decent cell morphology.


  • Open Access

    Case Report: Development of Diffuse Large B Cell Lymphoma a Long Time After Hairy Cell Leukemia

    by Zsófia F. Nagy, Kata Ferenczi, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter

    Hairy cell leukaemia (HCL) is a rare B cell malignancy with an indolent course leading to pancytopaenia due to bone marrow infiltration. It has been proposed that HCL patients are at risk of developing a secondary malignancy, with a marked likelihood of the development of other hematologic malignancies including Hodgkin lymphoma and high-grade non-Hodgkin lymphomas. Here, we present the case of two patients who developed diffuse large B cell lymphoma after a long course of hairy cell leukaemia. In the case of the female patient, we report on the occurrence of a third malignant disease, which is very uncommon. With our case descriptions we contribute to the very small number of similar cases reported.


  • Open Access

    Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax

    by Ambrus Gángó, Richárd Kiss, Péter Farkas, Eid Hanna, Judit Demeter, Beáta Deák, Dóra Lévai, Lili Kotmayer, Donát Alpár, András Matolcsy, et al.


    • 28 November 2016
      • Vol. 61  (1) , 6-11

    [The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].

    by Botond Timár

    Lymphoplasmacytic lymphoma is a rare low-grade B-cell lymphoma, which is composed of a mixture of small lymphocytes, plasmacytoid cells and plasma cells that typically infiltrate the bone marrow, but lymph nodes and rarely other organs can be involved as well. Waldenström macroglobulinaemia is a lymphoplasmacytic lymphoma with typical bone marrow involvement and is associated with detectable IgM paraproteins. The diagnosis of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM) can be challenging, due to similarities to other small B-cell lymphomas with plasmacytic differentiation and/or with IgM paraproteins. The recently discovered MYD88 mutation may help in the diagnosis, as it is present in over 90% of LPL/WMs. This short review covers the pathology of LPL/WM and offers some insight into the new molecular findings that may help in the diagnostic procedure and in the new therapeutic choices.

    • 23 February 2016
      • Vol. 60  (2) , 145-53

    [The pathology and genetic background of myeloma].

    by Botond Timár

    Plasma cell myeloma is a heterogeneous hematologic malignancy of plasma cells, occurring dominantly in the elderly population. It is now accepted that all myeloma cases are preceded by a clinically silent expansion of clonal plasma cells, known as monoclonal gammopathy of undetermined significance. Our knowledge on the genetics of myeloma is still limited and lags behind other well-characterized hematological malignancies. One of the reasons of this fact is the difficulty to induce metaphases within the malignant plasma cell population. With the development of new molecular techniques (microarrays and next generation sequencing), our understanding of the pathogenesis and progression of myeloma has been highly improved in the past years. This review offers an insight into this newly gained knowledge.